VANCOUVER, Aug. 2, 2019 /CNW/ – PRESS RELEASE – InMed Pharmaceuticals Inc., a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, has announced the appointment of Bruce S. Colwill, CPA, CA as Chief Financial Officer, effective Aug. 9, 2019.
Colwill joins InMed with over 25 years of experience in financial leadership roles. Prior to InMed, Colwill served as Chief Financial Officer of General Fusion Inc., a private clean energy company, since October 2016. Previously, Colwill was Chief Financial Officer at Entrée Resources Inc., a mineral exploration company, from February 2011 to March 2016. He has also held Chief Financial Officer roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Services Inc.
“We are delighted to have Mr. Colwill join the InMed leadership team at a pivotal time for the company,” commented Eric A. Adams, President and Chief Executive Officer. “As the CFO of multiple public and private companies, Mr. Colwill has executed a successful IPO as well as multiple equity and debt financings. His financial expertise and deep understanding of the capital markets will help ensure that InMed maintains a healthy balance sheet while continuing to execute on our broader strategic objectives.”
“InMed is clearly taking a leadership position in cannabinoid-based pharmaceuticals and manufacturing technology,” stated Colwill. “The combination of the company’s cutting-edge platform technology, combined with its stellar leadership team, is what drew me to this exciting opportunity. I look forward to joining the team at InMed to advance the company’s corporate initiatives and realize the full potential of InMed’s disruptive biosynthesis process and cannabinoid therapeutics.”
Contemporaneous with Colwill’s appointment, InMed will be consolidating the roles of Chief Financial Officer and Chief Business Officer into one position, that of Chief Financial Officer. Jeff Charpentier will be stepping down from the CFO role but will continue as part of the InMed team in a role with a reduced time commitment. In addition, CBO Josh Blacher has decided to leave InMed to pursue another opportunity in the investment management industry. Management has taken efforts to ensure a smooth transition.
“Jeff has made significant contributions to InMed as CFO which have helped position the company for success as we progress to our next stage of development. We would like to thank him for his outstanding work in the CFO role and are pleased that he will continue as part of the InMed team to provide his insights,” said Adams. “We would also like to thank Josh for his successful efforts introducing InMed to the institutional investment community and wish him all the best as he transitions back into the investment management industry.”
Published at Mon, 05 Aug 2019 20:08:00 +0000